In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: LivaNova’s current price exceeds its PERT-weighted fair value by 47%, indicating potential overvaluation with a high-confidence valuation consensus. DCF shows significant negative midpoint valuation, while other metrics like price/sales and analyst targets suggest higher ranges, revealing valuation disparities. Financial health scores show strong leverage with zero profitability and efficiency, raising risk despite growth potential.